Roche reports a strong start in 2019 and raises the outlook for the full-year

von Tobias Borgers | Sep 1, 2019 | Roche

Media Release Basel, 17 April 2019 Roche reports a strong start in 2019 and raises the outlook for the full-year Group sales increase 8%1 at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta,...

Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

von Tobias Borgers | Aug 26, 2019 | Roche

Media Release Basel, 14 May 2019 Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. Parties elect to refile Premerger...

Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents

von Tobias Borgers | Aug 24, 2019 | Roche

Media Release Basel, 16 May 2019 Roche’s personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents Phase I/II study of entrectinib, an investigational medicine, showed responses in all paediatric tumour...

Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia

von Tobias Borgers | Aug 19, 2019 | Roche

Media Release Basel, 16 May 2019 Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by...

Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases

von Tobias Borgers | Jul 29, 2019 | Roche

Media Release Basel, 02 June 2019 Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases Data will be presented at the...

Geschäftsführerwechsel bei MSD in Deutschland: Chantal Friebertshäuser folgt auf Dr. Susanne Fiedler

von Tobias Borgers | Jul 11, 2019 | MSD, Roche

Pressemitteilung Geschäftsführerwechsel bei MSD in Deutschland: Chantal Friebertshäuser folgt auf Dr. Susanne Fiedler Haar, 11. Februar 2019 – Chantal Friebertshäuser (45) ist mit Wirkung zum 1. März 2019 neue Vorsitzende der Geschäftsführung von MSD in Deutschland....